Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Chemical inhibition of FBXO7 reduces inflammation and confers neuroprotection by stabilizing the mitochondrial kinase PINK1
Yuan Liu, … , Bill B. Chen, Rama K. Mallampalli
Yuan Liu, … , Bill B. Chen, Rama K. Mallampalli
Published June 4, 2020
Citation Information: JCI Insight. 2020;5(11):e131834. https://doi.org/10.1172/jci.insight.131834.
View: Text | PDF
Research Article Neuroscience

Chemical inhibition of FBXO7 reduces inflammation and confers neuroprotection by stabilizing the mitochondrial kinase PINK1

  • Text
  • PDF
Abstract

Mitochondrial quality control is mediated by the PTEN-induced kinase 1 (PINK1), a cytoprotective protein that is dysregulated in inflammatory lung injury and neurodegenerative diseases. Here, we show that a ubiquitin E3 ligase receptor component, FBXO7, targets PINK1 for its cellular disposal. FBXO7, by mediating PINK1 ubiquitylation and degradation, was sufficient to induce mitochondrial injury and inflammation in experimental pneumonia. A computational simulation–based screen led to the identification of a small molecule, BC1464, which abrogated FBXO7 and PINK1 association, leading to increased cellular PINK1 concentrations and activities, and limiting mitochondrial damage. BC1464 exerted antiinflammatory activity in human tissue explants and murine lung inflammation models. Furthermore, BC1464 conferred neuroprotection in primary cortical neurons, human neuroblastoma cells, and patient-derived cells in several culture models of Parkinson’s disease. The data highlight a unique opportunity to use small molecule antagonists that disrupt PINK1 interaction with the ubiquitin apparatus to enhance mitochondrial quality, limit inflammatory injury, and maintain neuronal viability.

Authors

Yuan Liu, Travis B. Lear, Manish Verma, Kent Z.Q. Wang, P. Anthony Otero, Alison C. McKelvey, Sarah R. Dunn, Erin Steer, Nicholas W. Bateman, Christine Wu, Yu Jiang, Nathaniel M. Weathington, Mauricio Rojas, Charleen T. Chu, Bill B. Chen, Rama K. Mallampalli

×

Figure 2

Fbxo7 triggers mitochondrial injury.

Options: View larger image (or click on image) Download as PowerPoint
Fbxo7 triggers mitochondrial injury.
(A and C) BEAS-2B cells were nucleo...
(A and C) BEAS-2B cells were nucleofected with control or Fbxo7 plasmid for 48 hours or shRNAs for 72 hours. Cells were treated with 50 μM CCCP for 5 minutes where indicated, and then stained with JC1 (2 μM) for additional 20 minutes for confocal microscopic analysis. Scale bars: 10 µm. (B) BEAS-2B cells were nucleofected with control or Fbxo7 plasmid for 48 hours and then were treated with or without CCCP (20 μM) for 1 hour. The cells were stained with MitoSense Red and annexin V for flow cytometry analysis.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts